NuCana
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3 Lochside Way, Edinburgh, Midlothian, E...Phone Number
+44 1313571111Website
www.nucana.comRevenue
$39.3 MillionStock Symbol
NCNAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About NuCana
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying the company's ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing the company's proprietary technology, the company is developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's pipeline includes NUC-3373 and NUC-7738. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent and is in a Phase 1b/2 study in patients with metastatic colorRead more
NuCana Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NuCana your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if NuCana had a recent Job posting/layoffs
Check out if NuCana is spiking on competitors!
Check if NuCana has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when NuCana launches new products
NuCana, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once NuCana has new funding data
Earning: See what the market has to say on NuCana recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at NuCana
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined NuCana as Masked Content
Find more new buyers
Compare Similar Companies to NuCana
Compare insights from companies similar to NuCana, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NuCana is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NuCana is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NuCana.
NuCana financials insights
Gather financial insights about NuCana, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Stock Offering
$115M
NuCana Tech Stack
A closer look at the technologies used by NuCana
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Promotion
Executive Move
Executive Moves, Promotion
Project
Product Development, Product Management, Intellectual Property, Legal Affairs, Pharmaceuticals
Earnings
Earnings, Finance
Earnings
Earnings, Finance
NuCana News & Media
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant MelanomaNuCana Appoints Theresa Bruce as Chief Operating Officer
EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026.NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier Findings Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier FindingsNuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
EDINBURGH, United Kingdom, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the China National Intellectual Property Administration (“CNIPA”) has granted an important patent covering the composition of matter for NUC-7738. This patent (ZL 202010794701.2) is expected to serve as a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition of matter patent covers the chemic
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NuCana
Sign Up For FreeTo access detailed company insights
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying the company's ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part... Read More
